SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending after reporting substantial year-over-year revenue growth and expanded global approvals for its ANKTIVA cancer therapies in new markets and indications like lung cancer. The community is buzzing with talk of a potential short squeeze, encouraging buying dips, and anticipating significant long-term upside as the company broadens its global commercial footprint.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a pivotal development underscored by its New Chemical Entity (NCE) status and patent protection until 2044. The community anticipates a significant re-rating and potential short squeeze, highlighting that this second recent FDA approval makes the company vastly undervalued compared to prior rejected buyout offers.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing a significant downturn after its CagriSema weight-loss drug demonstrated slightly lower efficacy than a competitor in a recent trial, prompting community discussion on whether the market's reaction is an overcorrection despite NVO's strong financial position and other successful products.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after releasing positive Phase 2 trial data for its lead drug sonelokimab in axial spondyloarthritis, showing high efficacy and signs of disease modification ahead of its Investor Day. The community views this, coupled with a strong cash position and high short interest, as a significant re-rating catalyst, anticipating a substantial surge and potential for best-in-class market positioning.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending following a $25 million direct offering of common stock at $5.00 per share to institutional investors, igniting community debate over whether it signals institutional confidence in the company's MST technology for AI chips and GAA architectures or represents a dilutive "rugpull".

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx ($ACLX) is surging after Gilead Sciences ($GILD) announced its acquisition for $115 per share in cash, valuing the cancer therapy developer at up to $7.8 billion. The biotech community is enthusiastically discussing the significant premium and the potential for increased M&A activity in the oncology sector.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is trending after its latest earnings revealed increased U.S. market share and continued international same-store sales growth, alongside a significant dividend hike, signaling strong operational execution. The community is discussing these results and an increased stake by notable investors as key drivers, highlighting the company's "Hungry for MORE" strategy and resilience in the restaurant sector.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

Recent IPO AIDX is trending due to extreme volatility and significant community debate, with some labeling it a 'pump and dump' anticipating further declines while others expect a major bounce, all within a broader sector experiencing pressure.

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) is highly volatile following its recent strong earnings report and raised guidance, with the stock experiencing a dramatic sell-off that has ignited community debate regarding whether it is an overreaction to the company's cited sequential Q1 test volume decline or a deeper re-evaluation of its valuation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending on the heels of its latest financial results, which exceeded expectations, and significant advancements across its neuroscience pipeline, including the priority review of AXS-05 for Alzheimer's disease agitation. Investors are keenly focused on the company's strong commercial momentum and path to cash flow positivity, with numerous analyst upgrades reflecting bullish sentiment despite initial market reactions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Great Elm Capital Group (NASDAQ:GECC) Trading Down 0.9% - Time to Sell?

Great Elm Capital Group (NASDAQ:GECC) Stock Price Down 0.9% - What's Next...

Great Elm Group Q2 Earnings Call Highlights

Great Elm Group (NASDAQ:GEG) executives said fiscal 2026 second-quarter results were heavily influenced by market-driven valuation declines in a difficult environment for business development...

Great Elm Group (NASDAQ:GEG) Shares Up 0.4% - Here's What Happened

Great Elm Group (NASDAQ:GEG) Trading Up 0.4% - Here's Why...

Great Elm Capital Group (NASDAQ:GECC) Shares Up 2.8% - Here's Why

Great Elm Capital Group (NASDAQ:GECC) Trading 2.8% Higher - Time to Buy...

Great Elm Group (NASDAQ:GEG) Shares Up 1.5% - Still a Buy?

Great Elm Group (NASDAQ:GEG) Trading Up 1.5% - Here's Why...

Matthew Kaplan Purchases 19,650 Shares of Great Elm Capital Group (NASDAQ:GECC) Stock

Great Elm Capital Group, Inc. (NASDAQ:GECC - Get Free Report) CEO Matthew Kaplan acquired 19,650 shares of the stock in a transaction dated Friday, November 7th. The stock was bought at an average...

Insider Buying: Great Elm Capital Group (NASDAQ:GECC) CEO Purchases 19,650 Shares of Stock

Great Elm Capital Group, Inc. (NASDAQ:GECC - Get Free Report) CEO Matthew Kaplan acquired 19,650 shares of the firm's stock in a transaction on Friday, November 7th. The stock was purchased at an...

Janney Montgomery Scott Has Lowered Expectations for Great Elm Capital Group (NASDAQ:GECC) Stock Price

Janney Montgomery Scott cut their price objective on Great Elm Capital Group from $12.00 to $10.00 and set a "neutral" rating for the company in a report on Thursday...

Great Elm Capital Group, Inc. to Issue Quarterly Dividend of $0.37 (NASDAQ:GECC)

Great Elm Capital Group, Inc. (NASDAQ:GECC) announced a quarterly dividend on Tuesday, November 4th. Investors of record on Monday, December 15th will be paid a dividend of 0.37 per share by the...

Great Elm Group, Inc. engages in providing investment management and real estate management services. It focuses on the business of growing a portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. The company was founded in 1994 and is headquartered in Palm Beach Gardens, FL.

Current Price	$2.08
Prev Close	$2.08
Open	$2.08
Dividend Yield	0.00%
50-Day Moving Average	$2.33
Beta	0.20
Avg. Volume	8,364.60
PE Ratio	-3.79

52-Week High	$3.51
52-Week Low	$1.76
Market Capitalization	$68.11M
EPS (Annual)	$0.3321
Price to Book	1.16
Revenue Per Employee	$326,320.00

GEG
Great Elm Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GEG News

GEGGreat Elm Group Inc